Exalpha Biologicals, Inc. Announces Acquisition of Leading Producer of Egg-Derived Antibodies Gallus Immunotech Inc.
Continues expansion of its range of Antibodies and Reagents that answer real needs
Shirley, Massachusetts, USA – June 6th, 2018 – Exalpha Biologicals, Inc., founded over 20 years ago and dedicated to accelerating the pace of discovery in the life science arena announces the acquisition of Gallus Immunotech Inc., which is effective from today 6th June 2018.
Gallus Immunotech, Inc. founded in 1994 to promote the remarkable and humane process of developing chicken polyclonal antibodies. Chicken antibodies produce immunoglobulin (IgY) which Gallus Immunotech, Inc. has now matured into a business with world class IgY expertise and a world-wide customer base.
Exalpha Biologicals, Inc. are tremendously excited at the opportunity to both welcome Gallus Immunotech Inc. to the Exalpha family and the offer the extended range of products and additional value that can now be offered to new and existing customers.
“We are very pleased with the acquisition of Gallus Immunotech, Inc., and the extended quality range that will now be available to our customers” said Peter Rutten, Exalpha Biologicals, Inc. Operations Director. “We look forward to working with all the Gallus customers and serving their needs”
For all enquiries or orders you will need to contact Exalpha Biologicals, Inc.:
General Enquiries: email@example.com
Exalpha Biologicals, Inc.
2 Shaker Road
About Exalpha Biologicals, Inc.
Exalpha, the Boston based life science company, specializes in the provision of high quality research products such as apoptosis & proliferation assays along with enzymes and antibodies. Founded 20 years ago, it is based in Shirley, Boston and dedicates itself to selling antibodies, kits and reagents to the Research community.